lymphoma | UNC Project-Malawi Cancer

The University of North Carolina at Chapel Hill

Skip to main content

UNC School of Medicine | Institute for Global Health & Infectious Diseases

Poor Survival Outcomes Reported in Malawian Cohort With Indolent Lymphomas

May 2026 Patients with indolent lymphomas in Malawi mainly treated with chemotherapy alone experienced poor survival outcomes, despite exhibiting disease characteristics similar to those of patients in high-income countries. This is according to a study published in Blood Global Hematology.1 “This study highlights the need to expand access to affordable cancer...

Hodgkin lymphoma treatment patterns and outcome disparities in low- and middle-income countries

October 2025 Hodgkin lymphoma (HL) incidence is on the rise globally with higher morbidity and mortality rates in low- and middle-income countries (LMICs). The role of treatment patterns in these disparities is not well understood. We systematically reviewed the published literature on adult HL in LMICs with specific focus on...

High-Dose Methotrexate Usage Without Drug-Level Monitoring in Advanced Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting in Malawi.

March 2025 PURPOSE Excellent survival for advanced (stages II with high lactate dehydrogenase, III, and IV) pediatric mature B-cell non-Hodgkin lymphoma (MB-NHL) has been achieved with intensive regimens, but adoption in sub-Saharan Africa is limited by inadequate supportive care. We provide real-world data on treating advanced MB-NHL with high-dose methotrexate...

Orbital T-cell lymphoblastic lymphoma in children: A case report and review of literature

October 2024 Full Paper

Rituximab is associated with an increased risk of malaria among adult lymphoma patients in Malawi: a prospective observational cohort

December 2025 BACKGROUND Rituximab has become a standard of care for many B-cell neoplasms, such as diffuse large B-cell lymphoma (DLBCL). However, the impact of rituximab-induced B-cell deficiency on the risk of malaria for patients residing in endemic areas is unknown. Thus, this study evaluated the incidence of and risk...

Aetiology, susceptibility and outcomes of fever in patients receiving chemotherapy in Malawi: a prospective study

October 2024 Objectives: To evaluate causes of fever, including resistance patterns, in patients undergoing cancer treatment in Malawi. Methods: In this prospective cohort study, enrolled patients undergoing chemotherapy at Kamuzu Central Hospital in Lilongwe, Malawi were given a thermometer. If a temperature of ≥38°C was recorded, they were instructed to...

Transcriptome profiling of pediatric extracranial solid tumors and lymphomas enables rapid low-cost diagnostic classification

August 2024 Approximately 80% of pediatric tumors occur in low- and middle-income countries (LMIC), where diagnostic tools essential for treatment decisions are often unavailable or incomplete. Development of cost-effective molecular diagnostics will help bridge the cancer diagnostic gap and ultimately improve pediatric cancer outcomes in LMIC settings. We investigated the...

HIV and prior exposure to antiretroviral therapy alter tumour composition and tumour: T-cell associations in diffuse large B-cell lymphoma.

May 2024 Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma worldwide, accounting for up to 40% of new non-Hodgkin Lymphoma (NHL) globally. People living with HIV are up to 17 times more likely to develop NHL, and as such, DLBCL is the leading cause of cancer...

HIV infection and ART exposure affect tumor TCR repertoire of diffuse large B cell lymphoma

May 2024 The most common subtype of lymphoma globally, diffuse large B cell lymphoma (DLBCL), is a leading cause of cancer death in people with HIV. The restructuring of the T cell compartment because of HIV infection and antiretroviral therapy (ART) may have implications for modern treatment selection, but current...

. Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study

March 2024 Background: ABVD (doxorubicin, bleomycin, vinblastine, and dexamethasone) is a proven, curative regimen for Hodgkin lymphoma (HL). Prospective data describing HL treatment in sub-Saharan Africa are limited. We aimed to fill this knowledge gap, using data from Malawi. Methods: We report a prospective observational cohort of HL (aged ≥...